{"id":829991,"date":"2025-03-26T08:43:07","date_gmt":"2025-03-26T12:43:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/"},"modified":"2025-03-26T08:43:07","modified_gmt":"2025-03-26T12:43:07","slug":"silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/","title":{"rendered":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment"},"content":{"rendered":"
\n

\n
\n Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials<\/em>
\n <\/strong>\n <\/p>\n

SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).<\/p>\n

\u201cThis IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an IND for SPC-15,\u201d said Eric Weisblum, CEO of Silo. \u201cWe are following the FDA\u2019s helpful responses to our pre-IND submission, which provide a clear path to an IND submission to first-in-human clinical studies.\u201d<\/p>\n

Silo Pharma completed a pre-IND meeting in September 2024 to align with the FDA on the 505(b)(2) regulatory pathway for approval of SPC-15 and review the Company\u2019s proposed plan to support opening an IND.\u00a0The FDA\u2019s 505(b)(2) drug development route can significantly shorten clinical timelines for FDA approval and reduce drug development costs.<\/p>\n

\n About SPC-15<\/strong>
\n
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA\u2019s streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.<\/p>\n

\n About Silo Pharma<\/strong>
\n
Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company\u2019s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer\u2019s disease and multiple sclerosis. Silo\u2019s research is conducted in collaboration with leading universities and laboratories.\u00a0silopharma.com<\/a><\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This news release contains “forward-looking statements” within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words \u201ccould\u201d, \u201cbelieve\u201d, \u201canticipate\u201d, \u201cintend\u201d, \u201cestimate\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201ccontinue\u201d, \u201cpredict\u201d, \u201cpotential\u201d, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (\u201cSilo\u201d or \u201cthe Company\u201d) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company\u2019s technology platforms, retaining and expanding the Company\u2019s customer base, fluctuations in consumer spending on the Company\u2019s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.<\/p>\n

\n Contact<\/strong>
\n
800-705-0120
investors@silopharma.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). \u201cThis IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an IND for SPC-15,\u201d said Eric Weisblum, CEO of Silo. \u201cWe are following the FDA\u2019s helpful responses to our pre-IND submission, which provide a clear path … <\/p>\n

Continue reading “Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-829991","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSilo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). \u201cThis IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an IND for SPC-15,\u201d said Eric Weisblum, CEO of Silo. \u201cWe are following the FDA\u2019s helpful responses to our pre-IND submission, which provide a clear path … Continue reading "Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-26T12:43:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment\",\"datePublished\":\"2025-03-26T12:43:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/\"},\"wordCount\":554,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/\",\"name\":\"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==\",\"datePublished\":\"2025-03-26T12:43:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - Market Newsdesk","og_description":"Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (\u201cSilo\u201d or the \u201cCompany\u201d), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). \u201cThis IND-enabling safety study and our concurrent GLP-compliant pharmacokinetic and pharmacodynamic study, if successful, will provide the last preclinical data needed to open an IND for SPC-15,\u201d said Eric Weisblum, CEO of Silo. \u201cWe are following the FDA\u2019s helpful responses to our pre-IND submission, which provide a clear path … Continue reading \"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-26T12:43:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment","datePublished":"2025-03-26T12:43:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/"},"wordCount":554,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/","name":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==","datePublished":"2025-03-26T12:43:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMTA3OSM2ODM0NjA2IzUwMDA2OTMzOQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/silo-pharma-achieves-key-milestone-with-first-dosing-in-ind-enabling-glp-study-for-spc-15-as-a-groundbreaking-ptsd-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829991","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=829991"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/829991\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=829991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=829991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=829991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}